VBI Vaccines Announces Positive Phase 1 Data For EVLP Vaccine Candidate Against COVID-19; Stock Up

VBI Vaccines Inc. (VBIV) announced positive Phase 1 data from its Phase 1/2 trial of the first of its enveloped virus-like particle or eVLP COVID-19 vaccine candidates, VBI-2902a, in healthy adults age 18-54 years of age.

In Tuesday pre-market trade, VBIV was trading at $4.33 up $0.32 or 7.98%.

The company noted that the 5µg dose of VBI-2902a, which expresses an optimized SARS-CoV-2 spike antigen and is adjuvanted with aluminum phosphate, was generally well-tolerated and elicited potent immune responses significantly higher than those seen in human convalescent sera.

The data establish a robust human proof-of-concept, at a low dose without the use of a next-generation adjuvant, demonstrating the potency of the eVLP particulate delivery platform against COVID-19.

The study also supports the assessment of a one-dose booster regimen in seropositive individuals.

The company plans to assess VBI-2905a, our eVLP candidate that expresses the spike protein of the Beta (B.1.351) COVID-19 variant, in the next phase of the ongoing adaptive Phase 1/2 study, initiation of which is expected in the third quarter of 2021.

Additionally, the company said it is working hard to develop multivalent eVLP candidates, designed to increase the breadth of protection against COVID-19, and expects to initiate the first clinical study of one of these candidates in the first half of 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT